NCT05876221View on ClinicalTrials.gov

Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura

CompletedOBSERVATIONAL
Enrollment

223

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

March 30, 2025

Study Completion Date

March 30, 2025

Conditions
Acquired Thrombotic Thrombocytopenic Purpura
Interventions
DRUG

Cablivi

Patients with immune Thrombotic Thrombocytopenic Purpura, who have been treated with caplacizumab (Cablivi®)

Trial Locations (1)

Unknown

University Hospital of Cologne, Cologne

All Listed Sponsors
lead

University of Cologne

OTHER

NCT05876221 - Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura | Biotech Hunter | Biotech Hunter